Published 8 days ago • loading... • Updated 6 days ago

Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting

Vanda reported that its randomized controlled study showed tradipitant, an oral NK-1 receptor antagonist, reduced GLP-1 induced nausea and vomiting in overweight and obese adults.
Amid a $50 billion global GLP-1 agonist market, gastrointestinal side effects drive early discontinuation, imposing substantial costs on patients and payors and creating unmet need for adjunctive therapies.
Using a rapid 1 mg Wegovy challenge, the trial of 116 participants pretreated with tradipitant 85 mg twice daily met endpoints with 29.3% experiencing vomiting versus 58.6% on placebo, with `p=0.0016`.
Vanda will evaluate regulatory and development steps, anticipating a Phase III program in the first half of 2026 and FDA review with a PDUFA target action date of December 30, 2025.
Supporting evidence from motion-sickness studies shows tradipitant can mitigate GLP-1 nausea, reducing 30-50% discontinuation rates, aligning with prior trials in over 800 individuals.

Insights by Ground AI

58 Articles

WBOC 16

+55 Reposted by 55 other sources

Center

Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting

Vanda's Tradipitant Study Success Positions it as Key Adjunct in $50B+ Global GLP-1 Agonist Market

7 days ago

Read Full Article

stocktitan.net

Vanda Pharma (Nasdaq: VNDA) Tradipitant cuts GLP-1 vomiting 50% in $50B market

Randomized trial in 116 overweight adults showed vomiting in 29.3% on tradipitant vs 58.6% placebo, with key nausea endpoint also met; Phase III planned for 2026.

7 days ago

Read Full Article